Published in Cancer Immunol Immunother on June 20, 2012
Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res (2014) 0.94
Current trends of anticancer immunochemotherapy. Oncoimmunology (2013) 0.91
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget (2015) 0.83
Immunological off-target effects of standard treatments in gastrointestinal cancers. Ann Oncol (2013) 0.81
Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma. J Immunol (2014) 0.80
Chemotherapy remains an essential element of personalized care for persons with lung cancers. Ann Oncol (2016) 0.77
IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice. Age (Dordr) (2014) 0.76
A review of the importance of immune responses in luminal B breast cancer. Oncoimmunology (2017) 0.75
Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol (2007) 1.74
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol (2003) 1.62
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol (2013) 1.59
Adjuvant chemotherapy for early colon cancer: what survival benefits make it worthwhile? Eur J Cancer (2010) 1.55
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol (2011) 1.29
Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden. Clin Cancer Res (2010) 1.25
Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One (2009) 1.24
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol (2008) 1.19
Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med (2007) 1.19
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother (2008) 1.18
A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology (2013) 1.11
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One (2013) 1.08
Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial. BMC Cancer (2011) 1.03
The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol (2012) 1.01
Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol (2009) 0.99
Contribution of the immune system to the chemotherapeutic response. Semin Immunopathol (2011) 0.98
Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice. Aging Cell (2013) 0.97
The information and support needs of patients diagnosed with High Grade Glioma. Patient Educ Couns (2009) 0.93
Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk? Radiat Oncol (2014) 0.92
Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses. Cancer Immunol Immunother (2011) 0.90
Lung cancer clinicians' preferences for adjuvant chemotherapy in non-small-cell lung cancer: what makes it worthwhile? Lung Cancer (2011) 0.87
IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. Int Immunol (2012) 0.87
The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimates. J Clin Oncol (2013) 0.86
Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. J Clin Neurosci (2011) 0.85
Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol (2014) 0.85
Current state and future directions of pleural mesothelioma imaging. Lung Cancer (2007) 0.85
Optimization of response classification criteria for patients with malignant pleural mesothelioma. J Thorac Oncol (2012) 0.84
Peripheral CD8(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies. Cancer Immunol Immunother (2012) 0.81
Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. Cancer Immunol Immunother (2005) 0.81
Rapid copper acquisition by developing murine mesothelioma: decreasing bioavailable copper slows tumor growth, normalizes vessels and promotes T cell infiltration. PLoS One (2013) 0.81
MexTAg mice exposed to asbestos develop cancer that faithfully replicates key features of the pathogenesis of human mesothelioma. Eur J Cancer (2010) 0.81
The antioxidants vitamins A and E and selenium do not reduce the incidence of asbestos-induced disease in a mouse model of mesothelioma. Nutr Cancer (2012) 0.80
Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma. J Thorac Oncol (2013) 0.80
Novel targeted therapies and vaccination strategies for mesothelioma. Curr Treat Options Oncol (2011) 0.79
Mechanisms of cisplatin-induced cell death in malignant mesothelioma cells: role of inhibitor of apoptosis proteins (IAPs) and caspases. Int J Oncol (2012) 0.79
Synthesis and antimalarial evaluation of novel isocryptolepine derivatives. Bioorg Med Chem (2011) 0.79
Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? Lung Cancer (2013) 0.78
Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol (2013) 0.78
Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions. J Thorac Oncol (2014) 0.78
Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy? Future Oncol (2014) 0.78
Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model. J Immunother (2005) 0.77
Dietary vitamin D supplementation does not reduce the incidence or severity of asbestos-induced mesothelioma in a mouse model. Nutr Cancer (2014) 0.77
Marked functional improvement after combined chemoradiotherapy for cervical spine glioblastoma causing quadriparesis in an adolescent. BMJ Case Rep (2014) 0.75
Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12. Cancer Gene Ther (2003) 0.75
Chemotherapy induced nausea and vomiting--prevention and treatment. Aust Fam Physician (2007) 0.75
Basic science funding in Australia: lessons from the EU. Nat Immunol (2002) 0.75